Feasibility · Type 2 diabetes · Phase II–III
Type 2 diabetes trial feasibility, cited to its source.
Type 2 diabetes has a large prevalent population, so the feasibility risk shifts from "are there enough patients" to "can we enroll fast enough against heavy competition and tight eligibility windows." Background-therapy and HbA1c criteria do most of the cohort filtering.
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
- Large prevalence is offset by intense trial competition for the same well-controlled patients.
- HbA1c windows and background-therapy requirements narrow eligibility significantly.
- Cardiovascular-outcome and renal endpoints change site type and duration dramatically.
- Mature mechanism precedent supports directional PTRS priors.
Grounded in public data
For type 2 diabetes, the verdict draws primarily on ClinicalTrials.gov, AACT, PubMed, FDA — every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. See the full data sources and compare other indications.
See a cited verdict for type 2 diabetes.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.